3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
32
Phase NA
15
Phase 2
12
Phase 1/2
12
Phase EARLY_PHASE1
3
Phase 3
2
Phase 4
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
37
Genitourinary
2
Breast
2
Thoracic
1
Sarcoma
1
Other
1
Head & Neck
1
Gynecologic
1
Dermatologic
1
Conditions
Keratosis, Actinic
46
Melanoma
27
Skin Neoplasms
14
Carcinoma, Basal Cell
9
Lymphoma, T-Cell, Cutaneous
8
Neoplasm Metastasis
5
Mycosis Fungoides
5
Lung Neoplasms
5
Keratosis
5
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma
3
Breast Neoplasms
3
Uveal Melanoma
2
Skin Diseases
2
Sezary Syndrome
2
Prostatic Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Waldenstrom Macroglobulinemia
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Substitutes
1
Seroma
1
Renal Transplant Patients at High-risk for Skin Cancer
1
Psoriasis
1
Pituitary Neoplasms
1
Pituitary ACTH Hypersecretion
1
Interventions
Sevoflurane
1
Propofol
1
Isoflurane
1
Desflurane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Colonic Neoplasms
×
Dermatologic
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled